Treatment News

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News


March 31, 2014
Daclatasvir/Olysio Combo Effectively Treats Hep C Genotype 1b
Low-dose daclatasvir and Olysio (simeprevir) cured a relatively high proportion of people with genotype 1b of hepatitis C, but just two thirds of 1b's.
Failure to Awaken Dormant Cells Deals Blow to HIV Cure Research
A laboratory at Johns Hopkins University has failed in its recent quest to find a drug that can reverse the latent state of HIV-infected immune cells that are a component of the viral reservoir. 
March 28, 2014
PrEP Adherence Varies Greatly Between Cities
Adherence to Truvada as pre-exposure prophylaxis (PrEP) against HIV infection varied widely in studies conducted in three different cities.
March 27, 2014
Crystal Meth May Fuel HIV Disease Progression and Transmission
Crystal meth use appears to both spur HIV disease progression and increase the likelihood of transmission.
March 26, 2014
Supplies of Belly Fat-Reducing Egrifta Have Thinned Out
Theratechnologies has announced a major shortage of its drug Egrifta (tesamorelin, for injection), which reduces HIV-related excess belly fat.
March 25, 2014
Lawmakers Attack High Price of Gilead's Hep C Drug Sovaldi
The Food and Drug Administration approved the hep C med for use in people who also have HIV, making it the first FDA-backed treatment for coinfection.
Male Circumcision Lowers HIV Rates in Women as Well
Male circumcision, which reduces female-to-male HIV transmission by 60 percent, also reduces HIV rates in women, by a smaller margin of 15 percent.
March 24, 2014
Man Who Began HIV Treatment 5 Days In Appears Virus-Free
A man who contracted HIV about five days before starting PrEP and 12 days before starting HIV treatment appears virus-free several months later.
Sovaldi & Ribavirin Is Effective for HIV/HCV Population
Sovaldi and ribavirin cured 75 percent of those with genotype 1 of hepatitis C in a recent trial, while treatment-naive people with genotype 3 did not fare as well on a shortened regimen.
March 21, 2014
Viread During Pregnancy Lowers Babies’ Bone Density
Women who take Viread during pregnancy give birth to babies with lowered bone density, although the longterm implication of this finding is unclear.
Trial Looks at HIV Med Isentress as Possible MS Treatment
A British study is testing the HIV antiretroviral Isentress (raltegravir) as a possible treatment for the brain lesions of multiple sclerosis.
March 20, 2014
BMS’s Attachment Inhibitor Shows Promise
A promising trial of Bristol-Myers Squibb’s attachment inhibitor BMS-663068 raises hope of the introduction of a new HIV antiretroviral drug class.
Very Early HIV Treatment in Monkeys Limits Viral Reservoir
Very early treatment can help suppress the development of the viral reservoir in monkeys infected with SIV, HIV's simian cousin.
March 19, 2014
Isentress + Prezista Is Safe, Effective as First-Line HIV Therapy
A regimen of Isentress plus boosted Prezista was comparable in efficacy to a standard treatment with Truvada and Prezista.
Those With Both HIV and Hepatitis C Face High Liver Cancer Rates
HIV ramps up liver disease progression among those coinfected with hepatitis C, even in the face of antiretroviral treatment for HIV.
March 18, 2014
Common Cancers Are More Fatal Among People With HIV
HIV-positive Americans are more likely to die than those without the virus following a diagnosis with many common cancers.
Woman With Lupus Develops Powerful HIV Antibodies
Scientists have discovered a woman with both lupus and HIV who has developed broadly neutralizing antibodies that have controlled her HIV.
March 17, 2014
HIV-Positive Men’s Risk of Heart Attack May Be Dropping
While women are at high risk, the risk of heart attack for men with HIV appears to be dropping, at least in one specific, medically insured population.
Rare Apparent Lesbian HIV Transmission is Documented
The Centers for Disease Control and Prevention (CDC) has reported a rare case of apparent sexual transmission of HIV between two women.
March 14, 2014
Two in Five Gay Men ‘Serosort’ in an Attempt to Prevent HIV
About 40 percent of HIV-negative gay men restrict their sexual partners to those they perceive to share their serostatus in an attempt to prevent HIV.
Post-Exposure Microbicide Gel Shows Promise in Monkeys
An Isentress-containing microbicide gel prevents vaginal transmission of the simian cousin of HIV, SIV, when used as a post-exposure prophylaxis.
March 13, 2014
HIV Meds Greatly Benefit South Africans, But Favor Women
In South Africa, women have experienced far more of the dramatic gains in longevity resulting from the expansion of HIV treatment.
March 12, 2014
Targeting HIV in Drug Injectors Can Lower AIDS in Heterosexuals
HIV testing and counseling as well as needle exchange and drug programs for injection drug users appear to lower AIDS rates in heterosexuals.
Two Studies Raise Hopes for Female-Empowered HIV Prevention
After many years of failures, recent studies have moved researchers closer to a form of HIV prevention that women can use discreetly.
Tweets: A Possible HIV Risk Surveillance Tool
Twitter posts may one day serve as a means to monitor risky sexual behaviors in real time, helping hone HIV prevention efforts.
March 11, 2014
Lens Into Specific Antibody Evolution May Foresee HIV Vaccine
Researchers have mapped the development of a key HIV antibody, establishing scientific knowhow that may aid in the development of a vaccine.
Early Trial Paves the Way for Study of Long-Acting HIV Meds
A study investigating the HIV antiretrovirals GSK744 and Edurant has laid the groundwork for a future trial of long-acting versions of these drugs.
March 10, 2014
High HCV Cure Rates for BMS Set Stage for Triple Combo Pill
Twelve weeks of daclatasvir, asunaprevir and BMS-791325 cured more than 90% of treatment-naive people with genotype 1 of hep C.
HIV Spreads Readily Between Rural Ugandan Communities
Non-household transmission of HIV in Rakai, Uganda, is more likely to come from members outside of a community rather than from within.
March 08, 2014
Merck’s Hep C Drugs Show Promise for HIV Coinfection
Early results of Merck's combination hepatitis C therapy showed comparable safety between those with or without HIV, plus near-perfect cure rates.
Gilead’s Combo Therapy Cures Hep C in Just Six Weeks
Six weeks of the combination pill of ledipasvir and Sovaldi,  with or without GS-9669 or GS-9451, cured 95 to 100 percent of people with hep C.
March 07, 2014
Multi-Pronged Prevention Tactics Could Slash HIV Rates in IDUs
Using a multifaceted HIV prevention approach among injection drug uders could cut their new infections by more than 60 percent by 2040. 
March 06, 2014
99% Cure Rates for AbbVie’s Hep C Combo in Genotype 1b
AbbVie’s investigational triple-combination therapy cured close to 100 percent of people with genotype 1b of hepatitis C in a large Phase III trial.
Genetic HIV Therapy Aided by Drug to Boost CD4 Infusion
The drug Cytoxan is safe and relatively well tolerated and augments the uptake of immune cells genetically engineered to resist HIV.
Napo Loses Lawsuit Against Salix Over Diarrhea Drug
Napo Pharmaceuticals has lost its lawsuit against Salix Pharmaceuticals, in which the biotech firm accused Salix of deliberately thwarting Fulyzaq, the first drug approved to treat diarrhea resulting from HIV meds.
Young Black Gays in Atlanta Getting HIV at Breakneck Pace
A staggering 12 percent of young gay black men in Atlanta are contracting HIV each year.
March 05, 2014
Early Trial Raises Hopes of Quarterly PrEP Injections
An injectable long-acting antiretroviral succeeded in preventing rectal acquisition of SIV, the simian cousin of HIV, among monkeys.
Viral Suppression May Bring HIV Transmission Risk Close to Zero
Two years into a large study, there were no transmissions between HIV-positive people with a suppressed virus and their HIV-negative partners.
Genetically Modifying Cells to Resist HIV Shows Promise
A technique for genetically modifying the immune cells of people with HIV to resist the virus has shown promise in an early trial.
A Second Baby Born With HIV Is Now Apparently HIV Negative
A second baby born with HIV has no evidence of the virus in her body following an aggressive treatment regimen given shortly after birth.
March 04, 2014
Monthly PrEP Injections Show Promise in Female Monkeys
Monthly injections of the long-acting investigational antiretroviral GSK744 given to pigtail macaques prevented vaginal acquisition of simian HIV.
HIV Rates Fall in Kenya
Both the number of people living with HIV and the number of new annual infections have fallen in Kenya.
March 03, 2014
More MSM Get Tested for HIV, and More of Them Take Meds
Among gay and bisexual men, there has been a rise in the rate of those testing for HIV as well as in the rate of those with HIV who are on therapy.
March 02, 2014
Early Treatment Lowers HIV’s Spread and Benefits Economy
Early HIV treatment has expanded life expectancies, prevented new HIV cases and saved billions of dollars in skirted life expectancy losses.
More Treatment News

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ



Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Should the U.S. gay blood ban end?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.